InsidersTradesSigma
Track the 삼성바이오로직스 share price and the full directors' dealings record of the company, a publicly traded company based in South Korea. Shares are quoted on the KR market, under the authority of DART (FSS). Operating in the Health Care sector, 삼성바이오로직스 has logged 2 public disclosures. Market capitalisation: €70,686.3bn. The latest transaction was filed on 12 March 2026 (Other). Among the most active insiders: 컨두잇. The full history is accessible without an account.
2
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate 삼성바이오로직스 Strong Buy (bullish), based on 24 analysts. Average price target: ₩2,003,667.
Fundamental score
Ranked 9,575 of 29,056 companies
60.1
score / 100
Value36
Quality84
FCF yld1.1%
Earn yld2.5%
EV/EBITDA25.7x
ROE18%
Gross mgn55%
Net mgn39%
Debt/EBITDA0.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 12 March 2026
Acerca de 삼성바이오로직스
Samsung Biologics es una empresa surcoreana especializada en la fabricación de productos biofarmacéuticos. Cotiza en el mercado XKRX.